Épistaxis compliquant un traitement par anti-vitamine K et nouveaux anticoagulants oraux

Agence nationale de sécurité des médicaments et produits de santé (ANSM) Les anticoagulants en France états des lieux en 2014 et recommandations de surveillance [http://ansm.sante.fr/var/ansm_site/storage/original/application/26ed375830c56499badf0014eb3bb81b.pdf]. Haute Autorité de santé, 2013 Caisse nationale Assurance Maladie, 2013 Knauf, 2013, Dabigatran and kidney disease: a bad combination, Clin J Am Soc Nephrol CJASN, 8, 1591, 10.2215/CJN.01260213 Chen, 2012, Hemorrhagic complications associated with dabigatran use, Clin Toxicol Phila Pa, 50, 854, 10.3109/15563650.2012.721888 Ganetsky, 2011, Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant, J Med Toxicol, 7, 281, 10.1007/s13181-011-0178-y Kirchhof, 2016, 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur J Cardiothorac Surg, 50, e1, 10.1093/ejcts/ezw313 Ezekowitz, 2016, Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy), Circulation, 134, 589, 10.1161/CIRCULATIONAHA.115.020950 Bansilal, 2015, Am Heart J, 170, 10.1016/j.ahj.2015.07.006 Lopes, 2010, Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (Aristotle) trial: design and rationale, Am Heart J, 159, 331, 10.1016/j.ahj.2009.07.035 Piccini, 2014, Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial, Eur Heart J, 35, 1873, 10.1093/eurheartj/ehu083 Schulman, 2005, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, J Thromb Haemost JTH, 3, 692, 10.1111/j.1538-7836.2005.01204.x Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Eikelboom, 2011, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation clinical perspective, Circulation, 123, 2363, 10.1161/CIRCULATIONAHA.110.004747 Vogel, 2015, L’anticoagulation dans la fibrillation atriale du sujet âgé: point de vue du gériatre avec un focus sur les anticoagulants oraux directs, Rev Med Interne, 1, 22, 10.1016/j.revmed.2014.08.005 Barco, 2013, New oral anticoagulants in elderly patients, Best Pract Res Clin Haematol, 26, 215, 10.1016/j.beha.2013.07.011 García Callejo, 2014, Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant, Acta Otorrinolaringol Esp, 65, 346, 10.1016/j.otorri.2014.02.014 Kim, 2013, Coagulopathy and extremely elevated PT/INR after dabigatran etexilate use in a patient with end-stage renal disease, Case Rep Med, 2013, 131395, 10.1155/2013/131395 Albaladejo, 2014, Proper use of apixaban: an outline for clinical practice, J Mal Vasc, 39, 409, 10.1016/j.jmv.2014.09.002 Dizdar, 2007, Research for bleeding tendency in patients presenting with significant epistaxis, Blood Coagul Fibrinolysis Int J Haemost Thromb, 18, 41, 10.1097/MBC.0b013e3280110762 Soyka, 2010, Is severe epistaxis associated with acetylsalicylic acid intake ?, Laryngoscope, 120, 200, 10.1002/lary.20695 Kikidis, 2014, Is epistaxis associated with arterial hypertension? A systematic review of the literature, Eur Arch Otorhinolaryngol, 271, 237, 10.1007/s00405-013-2450-z